A subscription to JoVE is required to view this content. Sign in or start your free trial.

Method Article

Suspension Culture Production and Purification of Adeno-Associated Virus by Iodixanol Density Gradient Centrifugation for In Vivo Applications

4.7K views

⸱

DOI:

10.3791/66460

⸱

February 9th, 2024

 ,  , 
1Department of Pediatrics, University of Florida

In This Article

Summary

Adeno-associated virus is produced in suspension cell culture and purified by double iodixanol density gradient centrifugation. Steps are included to increase total virus yield, decrease the risk of virus precipitation, and further concentrate the final virus product. Expected final titers reach 1012 viral particles/mL and are suitable for pre-clinical in vivo use.

Abstract

This protocol describes recombinant adeno-associated virus (rAAV) production and purification by iodixanol density gradient centrifugation, a serotype-agnostic method of purifying AAV first described in 1999. rAAV vectors are widely used in gene therapy applications to deliver transgenes to various human cell types. In this work, the recombinant virus is produced by transfection of Expi293 cells in suspension culture with plasmids encoding the transgene, vector capsid, and adenoviral helper genes. Iodixanol density gradient centrifugation purifies full AAV particles based on particle density. Additionally, three steps are included in this now-ubiquitous methodology in order to increase total virus yield, decrease the risk of precipitation due to contaminating proteins, and further concentrate the final virus product, respectively: precipitation of viral particles from cell media using a solution of polyethylene glycol (PEG) and sodium chloride, the introduction of a second round of iodixanol density gradient centrifugation, and buffer exchange via a centrifugal filter. Using this method, it is possible to consistently achieve titers in the range of 1012 viral particles/mL of exceptional purity for in vivo use.

Introduction

Recombinant adeno-associated viral (rAAV) vectors are widely used tools for the treatment of genetic diseases, including spinal muscular atrophy, retinal dystrophy, and hemophilia A1,2,3. rAAV vectors are engineered to lack viral genes present in wild-type AAV4, a small, non-envelope icosahedral virus with a linear single-stranded 4.7 kb DNA genome. AAV was first discovered in the 1960s as a contaminant of adenovirus preparations5. Despite its small capsid size, which limits the size of the transgene that can be packaged to a maximum of 4.9 kb excluding ITRs6, AAV is useful for transgene delivery because it is non-pathogenic in humans, allows expression of transgene in many dividing and nondividing cell types, and has limited immunogenic effects7.

As members of the genus dependoparvovirus, the production of rAAVs relies on the expression of helper genes present in adenovirus or herpes simplex virus8. Several strategies to produce rAAV have been developed, but production in HEK293 cells transformed with the adenoviral E1A/E1B helper genes is the most established method used today9. The general approach of rAAV production begins with the transfection of HEK293 cells with three plasmids containing the transgene within inverted terminal repeats (ITRs), AAV rep and cap genes, and additional adenoviral helper genes, respectively. Seventy-two hours after transfection, cells are harvested and processed to purify rAAV containing the transgene.

In the development of new rAAV vectors for therapeutic purposes, a major goal is producing vectors with increased transduction efficiency. An increase in the transduction efficiency of target cells would mean a decrease in the necessary clinical dose of rAAV, thus decreasing the likelihood of adverse immunogenic effects ranging from antibody-mediated neutralization to acute toxicities10,11. To improve the transduction efficacy of rAAV vectors, alterations can be made to the packaged genome or to the capsid. Viable methods to tune transduction efficacy via packaged genome design include the incorporation of strong and tissue-specific promoters, thoughtful selection of mRNA processing elements, and coding sequence optimization to improve translation efficiency12. Alterations to the capsid are made with the goal of increasing tropism for target human cell types. Efforts towards developing new rAAV transgene delivery vector capsids are generally characterized by a focus on either rational design of AAV capsids with specific mutations targeting specific cell receptors or directed evolution to identify capsids with tropism for specific cell types from high-complexity combinatorial capsid libraries without targeting one specific receptor (although some groups combine these approaches)13,14,15. In the directed evolution approach, combinatorial capsid libraries are constructed using a particular serotype backbone with mutated variable regions on the capsid exterior16. Combinatorial capsid libraries are often constructed from AAV serotypes not originating in humans, decreasing the risk of preexisting immunity during clinical use10. Therefore, purification methods that can be applied to any serotype are ideal to eliminate the need for serotype-specific optimization for the less commonly used serotypes serving as backbones for these libraries.

Iodixanol density gradient centrifugation is utilized to purify high titers of rAAV with high infectivity17. In this protocol, rAAV is produced in suspension cell culture to decrease the amount of labor needed to produce large titers of AAV. A centrifugation step is also included to clear cell lysate to reduce the presence of contaminating proteins and decrease the risk of virus precipitation. This protocol is a cost-effective method to produce preparations of high-purity rAAV suitable for pre-clinical use.

Access restricted. Please log in or start a trial to view this content.

Protocol

The composition of the solutions and buffers used in this protocol are provided in Table 1.

SolutionComposition
AAV lysis buffer1.2 mL of 5 M NaCl solution
2 mL of 1 M Tris-HCl pH 8.5 solution
80 uL of 1 M MgCl2 solution
mQ water to 40 mL
AAV precipitation solution40 g PEG 8000
50 mL of 5 M NaCl solution
mQ water to 100 mL
15% iodixanol fraction7.5 mL OptiPrep
3 mL of 10X DPBS
6 mL of 5 M NaCl solution
30 uL of 1 M MgCl2 solution
mQ to 30 mL
25% iodixanol fraction12. 5 mL OptiPrep
3 mL of 10X DPBS
30 uL of 1 M MgCl2 solution
60 uL phenol red solution
mQ to 30 mL
40% iodixanol fraction33.3 mL OptiPrep
5 mL of 10X DPBS
50 uL of 1 M MgCl2 solution
mQ to 50 mL
60% iodixanol fraction50 mL OptiPrep
100 uL phenol red solution
AAV buffer solution8 mL of 5 M NaCl
20 uL of 10% Pluronic F-68
PBS to 200 mL

Table 1: Solution compositions for solutions used in this protocol.

1. Triple transfection of Expi293 cells

  1. Seed Expi293 cells (see Table of Materials) at an initial density of 5 x 105 viable cells (vc)/mL.
  2. Allow the cells to incubate at 37 °C with 8% CO2 and a shaker speed of 125 rpm until they reach a density of 3-5 x 106 vc/mL. Monitor cell density and viability using trypan blue exclusion with an automated cell counter (see Table of Materials).
  3. When cells reach the desired cell density, split them 1 to 10 by adding fresh media so that their total volume is ten times their original volume. If necessary, transfer cells into a bigger flask. Return to incubation.
  4. Continue to expand cells as described in steps 1.2-1.3 until they reach a density of at least 2 x 106 vc/mL in 250 mL of media in a 1 L flask.
  5. The day before transfection, dilute cells to 2 x 106 vc/mL in 250 mL of media, discarding excess cells as necessary. Incubate the cells overnight.
  6. On the day of transfection, centrifugate half of the cells at 58 x g for 5 min at 18 °C. Resuspend the cell pellet in the same volume (125 mL) of fresh medium. The cell viability should be close to 98%.
  7. Prepare two 50 mL conical tubes. Label one "PEI" and the other "DNA".
  8. In the conical tube labeled PEI, dilute 1.2 mL of PEI (Polyethylenimine, see Table of Materials) to a total volume of 12.5 mL in OptiMEM media.
  9. In the conical tube labeled DNA, prepare an equimolar solution of plasmid DNA to a total of 500 µg of DNA in a total volume of 12.5 mL in OptiMEM media.
  10. Add the DNA solution to the PEI solution, invert several times to thoroughly combine, and let incubate at room temperature for 10 min.
    NOTE: It is critical that the DNA-PEI solution is allowed to incubate for the full 10 min in order for PEI to form charged complexes with the DNA.
  11. After the DNA-PEI solution has incubated for 10 min, use a serological pipet to slowly apply the DNA-PEImax solution to the Expi293 cells. Return the transfected cells to the incubator and let them incubate for 72 h (Figure 1).

Fluorescence microscopy image of cells; optical excitation, emission analysis, 100 µm scale bar.
Figure 1: Expi293 cells expressing GFP two days after transfection. After transfection with a plasmid containing a gene for GFP, the Expi293 cells transiently express eGFP. The cell morphology is round. The image was captured with a 15 ms exposure time. Microscope images are acquired using an inverted microscope equipped with epi-fluorescence illumination and a 10x/0.30 objective. Scale bar = 100 µm. Please click here to view a larger version of this figure.

2. rAAV vector purification

  1. After 72 h, transfer the cells in suspension to two 250 mL conical tubes and spin them down at 415 x g for 10 min at 4 °C.
  2. Pour the supernatant media into a fresh 500 mL conical tube and store at 0 °C on ice for later processing.
  3. Resuspend each cell pellet in 10 mL of AAV lysis buffer (Table 1). Pool the two lysates together in one of the tubes. Rinse the other tube with an additional 5 mL of AAV lysis buffer, then add it to the pooled lysates. Freeze at -70 °C.
    NOTE: The experiment can be paused at this point. Store the supernatant media at -70 °C rather than on ice.
  4. Add 1:4 volume of AAV precipitation solution to the supernatant media from step 2.2. Invert several times to thoroughly mix and incubate at 0 °C on ice for at least 2 h or overnight.
  5. Centrifugate the incubated solution at 3000 x g for 1 h at 4 °C.
  6. Discard the supernatant and resuspend the pellet containing viral precipitate in 5 mL of AAV lysis buffer.
  7. Thaw the cell lysate at 37 °C in a water bath.
  8. Pool the viral precipitate with the cell lysate. This is the crude lysate. Rinse the centrifugation tube that contained the viral precipitate with an additional 5 mL of AAV lysis buffer and pool with the crude lysate.
  9. Freeze the crude lysate to -70 °C, then thaw at 37 °C. Repeat this cycle once more.
    NOTE: The crude lysate should not be left at 37 °C for any longer than is necessary to thaw it.
  10. Once thawed for the third time, immediately add 4 µL of benzonase to the crude lysate, invert to mix, and incubate for 30 min at 37 °C.
  11. Centrifugate the crude lysate for 10 min at 650 x g at 18 °C.
  12. Transfer the supernatant to a clean 50 mL conical tube. This is the crude virus. Discard the pellet.
  13. Centrifugate the crude virus for an additional 30 min at 3000 x g at 18 °C to clear contaminating proteins.
  14. Transfer the supernatant to a clean 50 mL conical tube. This is the clarified virus.
    NOTE: The experiment can be paused at this point. Freeze down the clarified virus to -70 °C.
  15. Set up the multichannel peristaltic pump with four peristaltic tubes (see Table of Materials). Attach capillaries to both ends of each tube.
  16. Place the capillaries on the input side of the pump in a beaker filled with deionized water. Place the capillaries on the output side of the pump in an empty beaker. Run the peristaltic pump at 25.0 rpm to flush the tubing with deionized (DI) water.
  17. When thoroughly flushed, empty the peristaltic tubing by running the pump until the tubing is filled only with air. Lay all capillaries on a clean lint free wipe.
  18. Place four ultracentrifuge tubes in a rack on the output side of the pump.
  19. Use a 10 mL serological pipet to carefully dispense 10 mL of clarified virus into each ultracentrifuge tube. Take care not to introduce air bubbles.
    NOTE: The volume of clarified virus in each tube can be stretched to up to 12 mL per tube, if necessary. Reduce the amount of 60% iodixanol appropriately in step 2.25 below.
  20. The clarified virus is underlaid with iodixanol fractions (Table 1) from lowest density to highest density using the peristaltic pump. The 15% fraction is added first, followed by the 25% fraction, the 40% fraction, and finally the 60% fraction. Transfer 22 mL (5.5 mL per ultracentrifuge tube) of the 15% iodixanol fraction into a clean 50 mL conical tube. Place the capillaries on the input side of the pump into the tube, taking care that all capillaries are touching the bottom of the tube.
  21. Start the pump and allow the tubing to fill with the iodixanol fraction. When the iodixanol fraction reaches the ends of the capillaries on the output side of the pump, stop the pump.
  22. Insert one output capillary into each ultracentrifuge tubes with clarified virus, taking care that the capillaries are touching the bottom of each ultracentrifuge tube.
    NOTE: It is of critical importance that there is no air left in the capillaries. Iodixanol may flow through the peristaltic tubing at slightly different rates, so ensure that each individual output capillary is completely filled with iodixanol before inserting it into the clarified virus. It may be necessary to stop and start the pump several times.
  23. Start the pump and allow the ultracentrifuge tubes to fill. When the last of the 15% fraction is about to be taken into the input capillaries, stop the pump. It is critical that no air bubbles enter the peristaltic tubing.
    NOTE: If air bubbles enter the input capillaries, the pump can be briefly run in the reverse direction to push them back out.
  24. Transfer 22 mL (5.5 mL per ultracentrifuge tube) of the 25% iodixanol fraction into the 50 mL conical tube. Take care that all capillaries are touching the bottom of the tube and start the pump. When the last of the 25% fraction is about to be taken into the input capillaries, stop the pump.
  25. Repeat step 2.24 with 20 mL (5 mL per ultracentrifuge tube) of the 40% iodixanol fraction and then with 24 mL (6 mL per ultracentrifuge tube) of the 60% fraction.
  26. If there is still unfilled volume left in the ultracentrifuge tube, continue to add more of the 60% fraction until the ultracentrifuge tubes are completely filled with liquid.
  27. Fill each tube until the lysate makes a dome over the top but does not overflow from the tube. Stop the pump and carefully remove each output capillary, taking care not to disturb the iodixanol gradient.
  28. Cap each ultracentrifuge tube with a spacer and load it into a Type 70 Ti rotor (see Table of Materials).
    NOTE: Ensure that the rotor is appropriately balanced. Do not attempt to operate the ultracentrifuge without proper training.
  29. Load the Type 70 Ti rotor into the ultracentrifuge and centrifugate at 489,000 x g for 1 h at 18 °C.
  30. After centrifugation, unload the rotor from the ultracentrifuge. Use needle nose pliers to carefully remove each ultracentrifuge tube from the rotor, taking care not to disturb the iodixanol gradient.
  31. Use a support ring stand with clamp to secure one ultracentrifuge tube.
  32. Attach a 20 GA needle to a 5 mL syringe and set aside. Use a lint-free wipe to remove the cap from the ultracentrifuge tube.
  33. Penetrate the wall of the ultracentrifuge tube with the needle about 3 mm below the 40%-60% iodixanol interface (Figure 2).
  34. Slowly aspirate the interface and part of the 40% fraction. Avoid aspirating the top of the 40% fraction, for a total draw of about 4 mL.
  35. Holding one finger over the open top of the ultracentrifuge tube, pull out the syringe and transfer the aspirated AAV fraction to a 50 mL conical tube. Discard the syringe in a sharps container. Discard the ultracentrifuge tube.
  36. Repeat steps 2.31-2.35 for each ultracentrifuge tube.
  37. Dilute the aspirated AAV fraction approximately two-fold in AAV lysis buffer to a volume of 40 mL.
  38. Flush the peristaltic tubing as described in steps 2.16-2.17.
    NOTE: The experiment can be paused at this point. Store the diluted AAV fraction at 0 °C overnight.
  39. Load 20 mL each of the diluted AAV fraction into two new ultracentrifuge tubes.
  40. For the second round of iodixanol density gradient centrifugation, the diluted AAV fraction is underlaid as described above using only 10 mL (5 mL per ultracentrifuge tube) of the 40% fraction and 14 mL (7 mL per ultracentrifuge tube) of the 60% fraction. Repeat steps 2.29-2.36 for ultracentrifugation and aspiration.
    NOTE: Before storing the peristaltic pump and tubing, flush out the tubing with DI water as described in steps 2.16-2.17.

Density gradient centrifugation result; test tubes with layered solutions showing macromolecule separation.
Figure 2: Iodixanol gradient with 40%-60% iodixanol interface labeled. (A) First iodixanol gradient. Phenol red is used in the 40% iodixanol and 60% iodixanol fractions. It appears as a different color because of the difference in pH between the two fractions. The arrow indicates where the syringe should be inserted to harvest the rAAV fraction, just below the 40%-60% iodixanol interface. (B) Second iodixanol gradient. Only the 40% and 60% iodixanol fractions are used in this step. The arrow indicates where the syringe should be inserted to harvest the rAAV fraction. Please click here to view a larger version of this figure.

3. Buffer exchange and virus concentration

  1. After obtaining the AAV fraction from the second round of iodixanol density gradient centrifugation, dilute it two-fold with AAV buffer solution.
  2. Equilibrate the centrifugal filter by adding 20 mL of AAV buffer solution to the top of the filter. Centrifugate the apparatus at 3000 x g at 18 °C for 5 min and discard flow through.
  3. Add the diluted AAV fraction to the centrifugal filter. Centrifugate the apparatus at 3000 x g at 18 °C for 5 min and discard flow through.
  4. Add 20 mL of AAV buffer solution to the top of the filter. Centrifugate the apparatus at 3000 x g at 18 °C for 5 min and discard flow through.
    NOTE: If the centrifugal filter membrane becomes blocked, causing the solution to flow through inefficiently, carefully use a P200 micropipette to draw up and down the solution in the top of the filter. Take extreme care not to touch the filter with the micropipette tip.
  5. Repeat step 3.4 twice more.
    NOTE: Ensure that the AAV is not overconcentrated by maintaining at least 1 mL of volume in the top of the filter. It may be necessary to adjust centrifugation times to prevent overconcentration. If AAV is overconcentrated, precipitation can occur.
  6. For a final titer in the range of 1012 vg/mL, spin down the virus to a final volume of about 1 mL.
    NOTE: Depending on the serotype backbone used and the packaging efficiency of the virus, you may have to concentrate the virus in a smaller volume.
  7. Use a p1000 micropipette to transfer the concentrated AAV from the top of the centrifugal filter into a microcentrifuge tube. Use a p200 micropipette to wash the centrifugal filter with 50 µL of AAV buffer to collect any remaining virus and pool with the rest of the concentrated AAV.
  8. Set aside a 2 µL aliquot of the concentrated AAV for titering. See Supplementary Table 1 to view ITR primers that can be used for qPCR.
  9. Pass the concentrated AAV through a 0.2 µm syringe filter to sterilize it.
    NOTE: When sterilizing a small volume, take care to select a syringe filter with a small diameter in order to minimize virus loss. Using a low-protein binding filter of a small diameter will result in minimal viral loss (data not shown).
  10. The sterilized AAV can be used immediately to transduce cells or stored at 4 °C for use within four weeks. It should be stored at -70 °C for longer-term storage.

Access restricted. Please log in or start a trial to view this content.

Results

This method can be used to obtain titers of at least 1012 viral particles per mL. A titer can be obtained (Figure 3) by qPCR using the ITR primers provided in Supplementary Table 1, by ddPCR, or by any other titering method. Suboptimal titers could result from using a cap gene encoding a capsid with poor packaging efficiency.

Another possible source of suboptimal results is the poor transduction efficiency of Expi293 cells. It ...

Access restricted. Please log in or start a trial to view this content.

Discussion

The double iodixanol density gradient purification protocol is the universal method because it is applicable to any AAV mutant variants, regardless of their receptor specificity. Early methods of AAV purification relied on particle density and included isopycnic centrifugation in CsCl and continuous sucrose density gradient centrifugation19. Later, serotype-specific approaches were developed, which made use of monoclonal antibodies bound to Sepharose columns20. A novel dens...

Access restricted. Please log in or start a trial to view this content.

Disclosures

The authors have no disclosures to report.

Materials

List of materials used in this article
NameCompanyCatalog NumberComments
5810 R benchtop centrifugeEppendorf22625501
8-channel peristaltic pump Watson-Marlow020.3708.00A
Automated cell counter NanoEntekEVE-MC
Avanti J-E high-speed centrifugeBeckman Coulter369001
BenzonaseThermo Scientific88701
Biological safety cabinetLabconco322491101
CO2 incubator with shaker Set at 8% CO2 and 37 °C
Conical centrifuge tubesThermo Scientific33965250 mL
Conical centrifuge tubesThermo Scientific33965015 mL
Disposable micro-pipetsFisherbrand21-164-2GCapillaries
Dulbecco's phosphate buffered saline without CaCl2 and MgCl2  (DPBS) (10x)Sigma-AldrichD1408
ECLIPSE Ts2R-FL inverted microscopeNikon
Expi293 Expression MediumGibcoA1435101
Expi293F cellsGibcoA14527
Filter tipsUSA Scientific1126-78101000 µL
Filter tipsUSA Scientific1120-8810200 µL
Filter tipsUSA Scientific1120-181020 µL
Filter tipsUSA Scientific1121-381010 µL
Hypodermic needlesTyco Healthcare82011220 GA x 1-1/2 A
Ice bucket with lidVWR10146-184
JS-5.3 rotorBeckman Coulter368690
Magnesium chloride solution (1 M)Millipore SigmaM1028-100ML
Metal stand and clamp Fisherbrand05-769-6Q
Microcentrifuge tubesEppendorf226000281.5 mL
Needle nose pliers
Optima XE-90 ultracentrifugeBeckman CoulterA94471
Opti-MEM I Reduced-Serum MediumGibco31985062
OptiPrep density gradient media (iodixanol)SerumwerkAXS-111454260% iodixanol solution
P1000 PipetGilsonF144059M
P2 PipetGilsonF144054M
P20 PipetGilsonF144056M
P200 PipetGilsonF144058M
Phenol red solutionSigma-AldrichP0290
Phosphate buffered saline (PBS)Sigma-AldrichP4474
Pipet-Aid XP pipette controllerDrummond Scientific4-000-101
Plasmid pCapsidDe novo or Addgene, etc. N/AWe used pACGrh74. 
Plasmid pHelperAddgene112867
Plasmid pTransgeneDe novo or Addgene, etc. N/AWe used pdsAAV-GFP.
Pluronic F-68 polyol solution (10%)Mp Biomedicals92750049
Polyethylene glycol 8000Research Products InternationalP48080-500.0
Polyethylenimine HCl Max (PEI-Max)PolysciencesNC1038561Dilute in water to 40 μM
Polypropylene centrifuge tubes, sterileCorning431123500 mL
Polypropylene centrifuge tubes, sterileCorning430776250 mL
Polypropylene Optiseal tubesBeckman Coulter361625
Serological pipettesAlkali ScientificSP250-B50 mL
Serological pipettesAlkali ScientificSP225-B25 mL
Serological pipettesAlkali ScientificSP210-B10 mL
Serological pipettesAlkali ScientificSP205-B5 mL
Shaker flasksFisherbrandPBV10001 L
Shaker flasksFisherbrandPBV50-0500 mL
Shaker flasksFisherbrandPBV250250 mL
Shaker flasksFisherbrandPBV12-5125 mL
Sodium chloride solution (5 M)Fisher ScientificNC1752640
Sterile syringesFisherbrand14-955-4585 mL
Syringe filterMilliporeSLGV013SL0.22 micron
Tris-HCl pH 8.5 (1 M)Kd MedicalRGE3363
Trypan blue solutionGibco15250061
Tube rack assemblyBeckman Coulter361646
Tube spacers (x4)Beckman Coulter361669
Tubing for peristaltic pumpFisher Scientific14190516
Type 70 Ti fixed-angle titanium rotorBeckman Coulter337922
Ultra low temperature freezerSet at -70 °C
Vivaspin 20 centrifugal concentratorSartoriusVS2041
Water bath Set at 37 °C

References

  1. Strauss, K. A., et al. Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: the Phase III SPR1NT trial. Nat Med. 28 (7), 1390-1397 (2022).
  2. Fuller-Carter, P. I., Basiri, H., Harvey, A. R., Carvalho, L. S. Focused update on AAV-based gene therapy clinical trials for inherited retinal degeneration. BioDrugs. 34 (6), 763-781 (2020).
  3. George, L. A., et al. Multiyear factor VIII expression after AAV gene transfer for hemophilia A. N Engl J Med. 385 (21), 1961-1973 (2021).
  4. Naso, M. F., Tomkowicz, B., Perry, W. L., Strohl, W. R. Adeno-Associated Virus (AAV) as a vector for gene therapy. Biodrugs. 31 (4), 317-334 (2017).
  5. Atchison, R. W., Casto, B. C., Hammon, W. M. cD. Adenovirus-associated defective virus particles. Science. 149 (3685), 754-756 (1965).
  6. Wu, Z., Yang, H., Colosi, P. Effect of genome size on AAV vector packaging. Mol Ther. 18 (1), 80-86 (2010).
  7. Samulski, R. J., Muzyczka, N. AAV-mediated gene therapy for research and therapeutic purposes. Annu Rev Virol. 1 (1), 427-451 (2014).
  8. Zolotukhin, S. Production of recombinant adeno-associated virus vectors. Hum Gene Ther. 16 (5), 551-557 (2005).
  9. Penaud-Budloo, M., François, A., Clément, N., Ayuso, E. Pharmacology of recombinant adeno-associated virus production. Mol Ther - Methods Clin Dev. 8, 166-180 (2018).
  10. Costa-Verdera, H., et al. Understanding and Tackling immune responses to adeno-associated viral vectors. Hum Gene Ther. 34 (17-18), 836-852 (2023).
  11. Ertl, H. C. J. Mitigating serious adverse events in gene therapy with AAV Vectors: Vector dose and immunosuppression. Drugs. 83 (4), 287-298 (2023).
  12. Pupo, A., et al. AAV vectors: The Rubik's cube of human gene therapy. Mol Ther. 30 (12), 3515-3541 (2022).
  13. Marsic, D., et al. Vector design tour de force: Integrating combinatorial and rational approaches to derive novel adeno-associated virus variants. Mol Ther. 22 (11), 1900-1909 (2014).
  14. Grimm, D., Zolotukhin, S. E Pluribus Unum: 50 Years of research, millions of viruses, and one goal-tailored acceleration of AAV evolution. Mol Ther. 23 (12), 1819-1831 (2015).
  15. Biswas, M., et al. Engineering and in vitro selection of a novel AAV3B variant with high hepatocyte tropism and reduced seroreactivity. Mol Ther - Methods Clin Dev. 19, 347-361 (2020).
  16. Perabo, L., et al. In vitro selection of viral vectors with modified tropism: the adeno-associated virus display. Mol Ther. 8 (1), 151-157 (2003).
  17. Crosson, S. M., Dib, P., Smith, J. K., Zolotukhin, S. Helper-free production of laboratory grade AAV and purification by iodixanol density gradient centrifugation. Mol Ther - Methods Clin Dev. 10, 1-7 (2018).
  18. Chan, C., Harris, K. K., Zolotukhin, S., Keeler, G. D. Rational design of AAV-rh74, AAV3B, and AAV8 with limited liver targeting. Viruses. 15 (11), 2168(2023).
  19. Schmidt, O. W., Cooney, M. K., Foy, H. M. Adeno-associated virus in adenovirus type 3 conjunctivitis. Infect Immun. 11 (6), 1362-1370 (1975).
  20. Grimm, D., Kern, A., Rittner, K., Kleinschmidt, J. A. Novel tools for production and purification of recombinant adenoassociated virus vectors. Hum Gene Ther. 9 (18), 2745-2760 (1998).
  21. Zolotukhin, S., et al. Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield. Gene Ther. 6 (6), 973-985 (1999).
  22. Clark, K. R., Liu, X., Mcgrath, J. P., Johnson, P. R. Highly purified recombinant adeno-associated virus vectors are biologically active and free of detectable helper and wild-type viruses. Hum Gene Ther. 10 (6), 1031-1039 (1999).
  23. Debelak, D., et al. Cation-exchange high-performance liquid chromatography of recombinant adeno-associated virus type 2. J Chromatogr B Biomed Sci App. 740 (2), 195-202 (2000).
  24. Burova, E., Ioffe, E. Chromatographic purification of recombinant adenoviral and adeno-associated viral vectors: methods and implications. Gene Ther. 12 (1), S5-S17 (2005).
  25. Adams, B., Bak, H., Tustian, A. D. Moving from the bench towards a large scale, industrial platform process for adeno-associated viral vector purification. Biotechnol Bioeng. 117 (10), 3199-3211 (2020).
  26. Grieger, J. C., Choi, V. W., Samulski, R. J. Production and characterization of adeno-associated viral vectors. Nat Protoc. 1 (3), 1412-1428 (2006).
  27. Florea, M., et al. High-efficiency purification of divergent AAV serotypes using AAVX affinity chromatography. Mol Ther Methods Clin Dev. 28, 146-159 (2022).
  28. Chamberlain, K., Riyad, J. M., Weber, T. Expressing transgenes that exceed the packaging capacity of adeno-associated virus capsids. Hum Gene Ther Methods. 27 (1), 1-12 (2016).
  29. Green, E. A., Hamaker, N. K., Lee, K. H. Comparison of vector elements and process conditions in transient and stable suspension HEK293 platforms using SARS-CoV-2 receptor binding domain as a model protein. BMC Biotechnol. 23 (1), 7(2023).
  30. Erbacher, P., Zou, S., Bettinger, T., Steffan, A. M., Remy, J. S. Chitosan-based vector/DNA complexes for gene delivery: Biophysical characteristics and transfection ability. Pharm Res. 15 (9), 1332-1339 (1998).
  31. Vandenberghe, L. H., et al. Efficient serotype-dependent release of functional vector into the culture medium during adeno-associated virus manufacturing. Hum Gene Ther. 21 (10), 1251-1257 (2010).
  32. Summerford, C., Samulski, R. J. Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions. J Virol. 72 (2), 1438-1445 (1998).
  33. Wright, J. F., et al. Identification of factors that contribute to recombinant AAV2 particle aggregation and methods to prevent its occurrence during vector purification and formulation. Mol Ther. 12 (1), 171-178 (2005).
  34. Gruntman, A. M., et al. Stability and compatibility of recombinant adeno-associated virus under conditions commonly encountered in human gene therapy trials. Hum Gene Ther Methods. 26 (2), 71-76 (2015).
  35. Srivastava, A. Rationale and strategies for the development of safe and effective optimized AAV vectors for human gene therapy. Mol Ther Nucleic Acids. 32, 949-959 (2023).
  36. Mullard, A. FDA approves first gene therapy for Duchenne muscular dystrophy, despite internal objections. Nat Rev Drug Discov. 22 (8), 610-610 (2023).
  37. Center for Biologics Evaluation and Research. Approved Cellular and Gene Therapy Products. US Food Drug Adm. , (2023).
  38. Kang, L., et al. AAV vectors applied to the treatment of CNS disorders: Clinical status and challenges. J Control Release Off J Control Release Soc. 355, 458-473 (2023).
  39. De Wolf, D., Singh, K., Chuah, M. K., VandenDriessche, T. Hemophilia gene therapy: The end of the beginning. Hum Gene Ther. 34 (17-18), 782-792 (2023).
  40. Simons, E. J., Trapani, I. The opportunities and challenges of gene therapy for treatment of inherited forms of vision and hearing loss. Hum Gene Ther. 34 (17-18), 808-820 (2023).

Access restricted. Please log in or start a trial to view this content.

Reprints and Permissions

Tags

Iodixanol GradientRecombinant AAVViral Vector ProductionGene TherapyViral Particle PurificationPEG Precipitation
Suspension Culture Production and Purification of Adeno-Associated Virus by Iodixanol Density Gradient Centrifugation for In Vivo Applications
Contact Us
Recommend to Library

Privacy

Terms of Use

Policies

Copyright © 2026 MyJoVE Corporation. All rights reserved.